Biggest News Aggregation in the World
📰 Beigene News

Page 10 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among […]
Xiao Dong Wang Johnv Oyler Xiaodong Wang Beigene Company Profile Morgan Stanley Securities Exchange Commission

DelveInsight Business Research, LLP: PD1 and PDL1 Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Incyte Corporation, Bristol-Myers Squibb, Novartis, Bayer, Beigene, Merck, AbbVie, and Others Expected to Propel Market

The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In
Shruti Thakur Bristol Myers Squibb Chugai Pharma Prnewswire Delveinsight Drug Administration Boehringer Ingelheim

BeiGene, Ltd. (NASDAQ:BGNE) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp grew its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 68.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,951 shares of the company’s stock after acquiring an additional 37,698 shares during the period. Van […]
United States Zurcher Kantonalbank Zurich Cantonalbank Xiao Dong Wang Johnv Oyler Xiaodong Wang Connor Clark Lunn Investment Management Ltd
Source: wkrb13.com

BeiGene (NASDAQ:BGNE) Issues Earnings Results

BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million during the quarter, compared to analysts’ expectations of $449.44 million. BeiGene had a negative net margin […]
Xiao Dong Wang Johnv Oyler Xiaodong Wang Goldman Sachs Group Inc Capital Group Private Client Services Inc Beigene Ltd

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BeiGene (NASDAQ:BGNE) Issues Quarterly Earnings Results

BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share for the quarter, topping the consensus estimate of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million for the quarter, compared to analyst estimates of $449.44 million. BeiGene had a negative return on equity […]
United States Xiao Dong Wang Xiaodong Wang Johnv Oyler Beigene Company Profile Beigene Ltd
Source: wkrb13.com

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort ... | May 3, 2023
United States New Zealand Beigene Novartis Beigene Novarti Suzanne Messere Ilya Rachman

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science